Harvard Bioscience Inc. (HBIO)
| Bid | 1.17 |
| Market Cap | 51.25M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.33 |
| PE Ratio (ttm) | -3.56 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 1.22 |
| Volume | 210,506 |
| Avg. Volume (20D) | 221,300 |
| Open | 1.25 |
| Previous Close | 1.24 |
| Day's Range | 1.16 - 1.26 |
| 52-Week Range | 1.16 - 4.70 |
| Beta | undefined |
About HBIO
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgic...
Analyst Forecast
According to 2 analyst ratings, the average rating for HBIO stock is "Strong Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago · seekingalpha.com
Harvard Bioscience, Inc. (HBIO) Q3 2024 Earnings Call TranscriptHarvard Bioscience, Inc. (NASDAQ:HBIO ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Kathryn Flynn - Corporate Controller James Green - Chairman, President and CEO ...